Interim Report January – September 2022
BioStock regarding TXP – December 20, 2022
BioStock – November 4, 2022
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors to help the body resolve inflammation. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by viruses like COVID-19.
-
February 1, 2023 RegulatoryPatrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
-
January 31, 2023 RegulatoryChange in number of shares and votes in SynAct Pharma
-
November 4, 2022 RegulatorySynAct Pharma publishes Q3 2022 interim report
-
August 5, 2022 RegulatorySynAct Pharma publishes Q2 2022 interim report
A MESSAGE FROM OUR CEO